Vaccinating against psoriasis, allergies and Alzheimer's a possibility, research shows

October 23, 2017 by Grant Hill, University of Dundee
Credit: CC0 Public Domain

Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against Alzheimer's disease.

Scientists led by Dundee's Dr John Foerster and Oxford's Professor Martin Bachmann, were able to take the protein coat of and incorporate a tetanus -derived protein structure known to stimulate the immune system in order to create vaccines to treat multiple .

The vaccine showed positive results in models of psoriasis and cat allergy and was shown to raise antibody levels thought to be beneficial in Alzheimer's disease. These vaccines can be either preventative, which is the hope for Alzheimer's but also therapeutic, meaning they can cure a disease like psoriasis after it has already been established.

More research is required to test the efficacy of the therapeutic in a clinical setting, but the Dundee-Oxford study raises the possibility of hundreds of thousands of people being spared the ravages of chronic diseases.

Dr Foerster said, "As an academic dermatologist with special interest in the immune system, my specific attention is on vaccines to be developed against chronic skin diseases. The idea is pretty simple – for diseases such as psoriasis or eczema, the newest and most effective medicines on the market are so-called 'antibodies', which are what you and I produce against bugs in a common cold.

"For chronic diseases, these antibodies are specially made against one of the body's own proteins. By blocking that single protein, the disease gets better. To use the example of psoriasis, a protein called Interleukin 17 needs to be active for the disease to progress. By creating a vaccine that stimulates the body to make antibodies against Interleukin 17 itself we can replace the need for frequent and expensive injections and make this type of treatment much more affordable and accessible to patients who could otherwise not afford specially made antibodies.

"Our research shows that this technique works in mice and, importantly, our new vaccine technology shows that it is likely to be a more effective type of vaccine than existing ones in older people. Since many patients with chronic conditions like psoriasis are elderly this technology may work much better to obtain effective vaccines."

The paper is published today in the journal npj Vaccines. The researchers are now looking to begin clinical testing of the vaccine and have already received regulatory approval to initiate testing in humans. Present antibodies for treatment typically need to be injected at least once a month to keep working, and cost around £10,000 per patient annually. A vaccine would offer much more affordable treatment.

In Alzheimer's, it is known that a protein called beta amyloid can cause brain damage resulting in inhibited function. Previous unsuccessful trials saw patients injected directly with against the same target but the new research suggests that starting the treatment – in the form of prophylactic vaccines – could provide a way of offering treatment even before the disease becomes clinically apparent. It is possible such prophylactic approach may work better and this could not be done using frequent antibody injections.

Professor Bachmann, Professor of Vaccinology at the Jenner Institute in Oxford, said, "Alzheimer`s disease usually develops in elderly people. The fact that the vaccine described here is optimised for old individuals seems therefore particularly helpful. An additional important aspect of the current work is that we developed a platform technology and are currently broadening our preclinical studies to vaccines against Parkinson`s disease as well as chronic pain."

Explore further: World-first trial for universal flu vaccine

More information: Andris Zeltins et al. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy, npj Vaccines (2017). DOI: 10.1038/s41541-017-0030-8

Related Stories

World-first trial for universal flu vaccine

October 4, 2017
The world's first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS.

DNA vaccine protects against toxic proteins linked to Alzheimer's

May 23, 2017
A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer's disease - without triggering severe brain swelling that earlier ...

Modified experimental vaccine protects monkeys from deadly malaria

May 22, 2017
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, modified an experimental malaria vaccine and showed that it completely protected four of eight ...

Investigational vaccine protects cattle from respiratory syncytial virus

March 10, 2017
A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according ...

Testing program monitors stability of vaccines for neglected tropical diseases

March 1, 2017
A new generation of vaccines for neglected tropical diseases is moving into clinical trials, and understanding the long-term stability and effectiveness of these vaccines over periods of storage is key to their success. Now, ...

Danish researchers behind vaccine breakthrough

April 26, 2016
A Danish research team from the University of Copenhagen has designed a simple technique that makes it possible to quickly and easily develop a new type of vaccines. The simple and effective technique will pave the way for ...

Recommended for you

Health insurance plans may be fueling opioid epidemic

June 22, 2018
Health care insurers including Medicare, Medicaid and major private insurers have not done enough to combat the opioid epidemic, suggests a study led by researchers at Johns Hopkins Bloomberg School of Public Health.

Overdose risk quintuples with opioid and benzodiazepine use

June 22, 2018
In the first 90 days of concurrent opioid and benzodiazepine use, the risk of opioid-related overdose increases five-fold compared to opioid-only use among Medicare recipients, according to a new study from the University ...

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.